Some reports indicated that CML-CP patients who achieved BCR/ABL1IS ≤10% at 3 months had a favorable outcome19; and some reports showed the CML-CP patients with low BCR-ABL1 transcript levels at diagnosing were easier to achieve molecular response1, 20. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.